Overview

Glycemic Holter Study (Continuous Glucose Monitoring) -

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The study will assess glycemic variability and optimized glycemic control in T2DM patients treated with a DPP-4 inhibitor as add-on therapy to metformin.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Sitagliptin Phosphate
Vildagliptin